To learn how to apply these adherence measures in conjunction with clinical biomarkers in routine clinical care.To understand the various methods available to measure adherence in airways disease.To learn how to apply these adherence measures in conjunction with clinical biomarkers in routine clinical care.What is the diagnosis of this woman with multiple respiratory infections in the previous year and a recent onset of progressive dyspnoea and wheezing? https//bit.ly/3bLgw2A.Heightened capsaicin cough sensitivity is independently associated with poor asthma control in moderate-to-severe asthma patients https//bit.ly/3mkbLkI.Most bronchogenic cysts are found incidentally and clinicians should be aware of an atypical case presentation. Total surgical resection is the treatment of choice of a bronchogenic cyst, especially in symptomatic patients. https//bit.ly/3uQrFXo.In children with persistent chylothoraces of unknown origin, intranodal lymphangiography can be used to help identify the source of a leak. This may enable embolisation with glue and coils to enable resolution of the chylothoraces. https//bit.ly/3gskhgJ.Inflammatory myofibroblastic tumour (IMT) is a rare neoplasm, most commonly described in children and young adults. We present a case of IMT in an elderly man. https//bit.ly/355wf8X.Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such, biologics cannot be recommended as an alternative to ICS therapy. Taking the time to assess adherence and provide interventions and education to support patients in asthma self-management has been shown to improve patient outcomes. It is therefore our responsibility as healthcare professionals to ensure that patients are supported, educated and motivated to adhere to ICS therapy before progressing to biologic therapies.Non-adherence to medicines is a significant clinical and financial burden, but successful strategies to improve it, and thus bring about significant improvements in clinical outcome, remain elusive. click here Many barriers exist, including a lack of awareness amongst some healthcare professionals as to the extent and impact of non-adherence and a dearth of skills to address it successfully. Patients may not appreciate that they are non-adherent, feel they cannot disclose it or underestimate its impact on their health in the short and longer term. In describing the evidence-based frameworks that identify the causal factors behind medicines taking (or not taking) behaviours, we can start to personalise interventions to enable individuals to make informed decisions about their treatments and thus overcome real and perceived barriers to adherence. To understand the underlying principles of why a patient may or may not take medicines as agreed.To choose targeted interventions to support better adherence.To understand the underlying principles of why a patient may or may not take medicines as agreed.To choose targeted interventions to support better adherence.What is the diagnosis of this man with a chronic dry cough and left hilar prominence on chest radiography? https//bit.ly/3fL7QMx.Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung disease with an estimated median survival of 2-5 years and a significant impact on quality of life (QoL). Current approved medications, pirfenidone and nintedanib, have shown a reduction in annual decline of forced vital capacity but no impact on QoL. The minimal clinically important difference (MCID) is a threshold value for a change in a parameter that is considered meaningful by the patient rather than solely relying on statistically significant change in the parameter. This review provides a brief overview of the MCID methodology along with detailed discussion of reported MCID values for commonly used physiological measures and patient-reported outcome measures in IPF. While there is no gold standard methodology for determining MCID, there are certain limitations in the MCID literature in IPF, mainly the choice of death, hospitalisation and pulmonary function tests as sole anchors, and pervasive use of distribution-based methods which do not take into account the patient's input. There is a critical need to identify accurate thresholds of outcome measures that reflect patient's QoL over time in order to more precisely design and evaluate future clinical trials and to develop algorithms for patient-oriented management of IPF in outpatient clinics. To understand the concept of MCID and the methods used to determine these values.To understand the indications and limitations of MCID values in IPF.To understand the concept of MCID and the methods used to determine these values.To understand the indications and limitations of MCID values in IPF.Ambulatory pneumothorax management in primary spontaneous pneumothorax is safe and feasible https//bit.ly/39w3EfD.Given the poor survival of lung cancer patients and the promising observations herein, future studies (RCTs) should further investigate both time- and dose-dependent effects of combination therapies across all categories of prevention of lung cancer. https//bit.ly/3hlYTtY.Pulmonary lymphoproliferative diseases are often associated with collagen diseases. In addition to treatment of the primary disease, additional treatments may be considered depending on the pathology presented in the case. https//bit.ly/3vKqsls.Simulation-based medical education is recognised as a highly effective training tool. Novel technologies such as breathing simulators have the potential to revolutionise how we train healthcare professionals to manage patients requiring NIV. https//bit.ly/3f4Hnt1.Can you diagnose this patient with vision problems? https//bit.ly/3vGe5qy.This is a general factsheet about COVID-19. It has some specific information for people with lung conditions, but most of the information will apply to everybody.The latest issue of Breathe focuses on "treatment burden" and the effects of this workload on patients read the introductory editorial by Chief Editor @ClaudiaCDobler https//bit.ly/3djgNeO.